Clinical Trial Update: Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for irofulven in recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer. The study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Irofulven (irofulven)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED